Salim Ben Yahia, Bechir Jelliti, Rim Kahloun, Rim Ghrissi, Salah Jenzeri, Moncef Khairallah (Monastir, Tunisia)


To manage inflammatory choroidal neovascularization (CNV) with intravitreal injection of bevacizumab, since conventional therapeutic options, including laser photocoagulation, surgery, corticosteroids, and verteporfin therapy, have potential limitations and are associated with a high rate of recurrences.


Three eyes of 3 young patients with inflammatory CNV were treated with a single intravitreal injection of 1.25 mg (0.05 mL) of bevacizumab. CNV was secondary to ocular toxoplasmosis in 2 patients and to pseudohistoplasmosis in one patient. Main outcome measures included changes in best-corrected visual acuity, central foveal thicknesses measured by optical coherence tomography, and leakage on fluorescein angiography. Follow-up was at least 12 months.

Effectiveness / Safety:

Complete closure of CNV occurred in all treated eyes, within the first 6 weeks of treatment, with subsequent improvement of visual acuity. No recurrence of CNV and no ocular or systemic side effects were observed during the follow-up period.

Take home message:

A single intravitreal injection of bevacizumab appears to be an effective and safe treatment modality for inflammatory CNV.